A team headed by Paul Carlier, Professor of Chemistry, Virginia Tech has received funding from the National Institutes of Health to carry out lead optimization on antimalarial drug candidate MMV008138. Carlier, who is Deputy Director of the Virginia Tech Center for Drug Discovery, is joined by Prof. Dan Slade (Biochemistry, Virginia Tech), Prof. Maria B. Cassera (Biochemistry & Molecular Biology, University of Georgia), and Dr. Max Totrov (Molsoft LLC, San Diego, CA). Each brings critical complementary expertise to this effort. They aim to find analogs of MMV008138 that have superior potency and selectivity for inhibition of IspD, an enzyme in the MEP pathway for isoprenoid precursor biosynthesis in the malaria parasite. Since mammals do not have this biochemical pathway, these analogs will have minimal “on-target” toxicity in humans.
- Exec. Committee Member Beth Sharlow on UVA’s Fiske Drug Discovery Lab
- KeViRx Selected as Part of BLUE KNIGHT™ Collaboration for Global Health Preparedness
- Desai Grant on Factor XIa Inhibitors Funded
- KeViRx-UVA-ODU Collaborative SBIR Grant funded
- Paul Carlier, Chair of the VaDDC, Receives Grant to Study Promising Antimalarial Drugs